BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Capmatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Capmatinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05488314-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Capmatinib: Phase 1/2 readout est. (NCT05488314)
DESCRIPTION:Capmatinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Me
 tastatic Non-small Cell Lung Cancer\nEstimated primary completion: 28 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capmatinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054883
 14
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642572-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capmatinib: Phase 2 readout est. (NCT05642572)
DESCRIPTION:Capmatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Comp
 aring Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Canc
 er That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capmatinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05642572
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03333343-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Capmatinib: Phase 1 readout est. (NCT03333343)
DESCRIPTION:Capmatinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NS
 CLC\nEstimated primary completion: 12 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capmatinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03333343
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03040973-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Capmatinib: Phase 2 readout est. (NCT03040973)
DESCRIPTION:Capmatinib\, phase 2.\nStudy: Study to Allow Patients Previousl
 y Participating in a Novartis Sponsored Trial to Continue Receiving Capmat
 inib Treatment as Single Agent or in Combination With Other Treatments or 
 the Combination Treatment Alone\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capmatinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03040973
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988475-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Capmatinib: Phase 2/3 readout est. (NCT06988475)
DESCRIPTION:Capmatinib\, phase 2/3.\nStudy: DETERMINE Trial Treatment Arm 0
 6: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
 \nEstimated primary completion: October 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/capmatinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06988475
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Capmatinib: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Capmatinib\, phase 2/3.\nStudy: DETERMINE (Determining Extended
  Therapeutic Indications for Existing Drugs in Rare Molecularly Defined In
 dications Using a National Evaluation Platform Trial) - Master Screening P
 rotocol\nEstimated primary completion: October 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capmatinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-1968@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Capmatinib: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Capmatinib\, phase 1/2.\nStudy: European Proof-of-Concept Thera
 peutic Stratification Trial of Molecular Anomalies in Relapsed or Refracto
 ry Tumors\nEstimated primary completion: February 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/capmatinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
